under the brand name Scenesse, an implantable form of afamelanotide has been approved in the EU, US, and elsewhere to reduce phototoxicity in erythropoietic protoporphyria (EPP)
The research team responsible for its development found that the peptide effectively induced GH release but had no effect on adrenocorticotropic hormone (ACTH), cortisol, or any other non-targeted hormones [6]
Guarantees confounded data
Research context What is in this stack
Manish Sahni, MD, focuses on personalized weight management plans
3 '(Cell)' , " (Trends in Endocrinology & Metabolism, IF 10.893)"